ArticleScientific reports2025
Detection of exon2-MED12 mutations in uterine leiomyomas from Syrian patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine leiomyomas (uLMs) are the most prevalent benign tumors of the female reproductive system. MED12 is one of the mediator complex subunits that has been implicated in uLMs pathogenesis. Somatic mutations in exon2-MED12 have been found in ~ 70% of uLMs. In this study, we investigated the status of exon2-MED12 in uLMs from Syrian patients. Sixteen leiomyomas from nine patients were assessed. Genomic DNA was isolated from tumors and exon2-MED12 was amplified by PCR and sequenced. Three specimens showed in frame point mutations consisted of missense substitutions in codon 44 (c.130). A novel insertion in codon 35 (c.103insG) was detected in one of the mutated cases and is expected to cause a frameshift in translation and an altered or truncated product. Some of the wild-type uLMs were collected from the same uteri that revealed mutations, which emphasizes the individuality of the uLM lesions and highlights the complexity of uLMs pathogenesis. The study is the first report from Syria on the topic and the second from the Arab world. It indicates genetic heterogeneity and independent clonal origin of the somatic mutations in exon2-MED12. In wild-type uLMs where exon2-MED12 mutations are absent, other players are in place and should be investigated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.